These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 36133304)
1. Dual-tracer PET/CT imaging to determine tumor heterogeneity in a patient with metastatic ACTH-secreting neuroendocrine neoplasm: A case report and literature review. Ryzhkova D; Mitrofanova L; Tsoy U; Grineva E; Schlyakhto E Front Endocrinol (Lausanne); 2022; 13():958442. PubMed ID: 36133304 [TBL] [Abstract][Full Text] [Related]
2. The Application of 68Ga-Somatostatin Analog and 18F-FDG PET/CT for Bone Metastasis from Neuroendocrine Tumors. Bai L; Xu J; Xu X; Zhang J; Liu X; Hu S; Chen J; Song S Neuroendocrinology; 2024; 114(8):775-785. PubMed ID: 38824926 [TBL] [Abstract][Full Text] [Related]
3. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. Abdulrezzak U; Kurt YK; Kula M; Tutus A Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719 [TBL] [Abstract][Full Text] [Related]
4. 68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Chordoma: Comparison With 18F-FDG. Derlin T; Sohns JM; Hueper K Clin Nucl Med; 2017 Apr; 42(4):e210-e211. PubMed ID: 28166150 [TBL] [Abstract][Full Text] [Related]
5. The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors. Novruzov F; Aliyev A; Wan MYS; Syed R; Mehdi E; Aliyeva I; Giammarile F; Bomanji JB; Kayani I Eur J Hybrid Imaging; 2021 May; 5(1):10. PubMed ID: 34181114 [TBL] [Abstract][Full Text] [Related]
6. Clinical impact of using [ Leupe H; Pauwels E; Vandamme T; Van den Broeck B; Lybaert W; Dekervel J; Van Herpe F; Jaekers J; Cleeren F; Hofland J; Brouwers A; Koole M; Bormans G; Van Cutsem E; Geboes K; Laenen A; Verslype C; Stroobants S; Deroose CM J Neuroendocrinol; 2024 Aug; 36(8):e13420. PubMed ID: 38837825 [TBL] [Abstract][Full Text] [Related]
7. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with Sampathirao N; Basu S J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019 [TBL] [Abstract][Full Text] [Related]
8. Biodistribution and first clinical results of Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the application of 18F-FDG and 68Ga-DOTATATE PET/CT in neuroendocrine tumors: A retrospective study. Hu X; Li D; Wang R; Wang P; Cai J Medicine (Baltimore); 2023 May; 102(19):e33726. PubMed ID: 37171344 [TBL] [Abstract][Full Text] [Related]
10. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Hindié E Theranostics; 2017; 7(5):1159-1163. PubMed ID: 28435455 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914 [TBL] [Abstract][Full Text] [Related]
12. A rare case of ectopic adrenocorticotropic hormone syndrome caused by a metastatic neuroendocrine tumor of the pancreas detected by 68Ga-DOTANOC and 18F-FDG PET/CT. Treglia G; Salomone E; Petrone G; Giaccari A; Rindi G; Rufini V Clin Nucl Med; 2013 Jul; 38(7):e306-8. PubMed ID: 23486330 [TBL] [Abstract][Full Text] [Related]
13. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact. Hayes AR; Furtado O'Mahony L; Quigley AM; Gnanasegaran G; Caplin ME; Navalkissoor S; Toumpanakis C Clin Nucl Med; 2022 Jan; 47(1):26-35. PubMed ID: 34874347 [TBL] [Abstract][Full Text] [Related]